Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Aug 19, 2025; 15(8): 103735
Published online Aug 19, 2025. doi: 10.5498/wjp.v15.i8.103735
Role of anlotinib plus albumin paclitaxel regimen in stage IV non-small cell lung cancer and mental state
Wei Zhang, Yun-Fang Zhao, Fei-Fei Liang, Xiao-Xia Liu, Jiang-Hong Liu, Jian-Dong Hao, Shu-Qin Cheng, Yan-Feng Wu
Wei Zhang, Yun-Fang Zhao, Fei-Fei Liang, Xiao-Xia Liu, Jiang-Hong Liu, Yan-Feng Wu, Department of Geriatrics, Zhangjiakou First Hospital in Hebei Province, Zhangjiakou 075000, Hebei Province, China
Jian-Dong Hao, Department of Respiratory, Zhangjiakou First Hospital in Hebei Province, Zhangjiakou 075000, Hebei Province, China
Shu-Qin Cheng, Department of Psychiatric, Wuhan University of Science and Technology Affiliated Tianyou Hospital, Wuhan 430064, Hubei Province, China
Co-first authors: Wei Zhang and Yun-Fang Zhao.
Author contributions: Zhang W and Zhao YF contributed equally to this study as co-first authors; Zhang W, Zhao YF, and Wu YF designed the research study; Liang FF, Liu XX, Liu JH, and Hao JD performed the primary literature search and data extraction; Zhang W and Zhao YF analyzed the data and wrote the manuscript; Cheng SQ and Wu YF were responsible for revising the manuscript for important intellectual content; all authors read and approved the final version.
Supported by Zhangjiakou Key R&D Program Projects, No. 2021108D.
Institutional review board statement: This study has been reviewed and approved by the Ethics Committee of Zhangjiakou First Hospital (Approval No. 2024128) and adheres to the principles outlined in the Declaration of Helsinki and the Ethical Review Measures for Biomedical Research Involving Human Subjects.
Informed consent statement: The decision to waive informed consent for this study has been approved.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No data available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Feng Wu, Assistant Professor, Department of Geriatrics, Zhangjiakou First Hospital in Hebei Province, No. 6 Baisi Lane, Xinhua Front Street, Qiaoxi District, Zhangjiakou 075000, Hebei Province, China. wuyanfeng1128@163.com
Received: February 26, 2025
Revised: March 21, 2025
Accepted: May 28, 2025
Published online: August 19, 2025
Processing time: 162 Days and 20 Hours
Abstract
BACKGROUND

Some studies have demonstrated that combination treatment with anlotinib and albumin-bound paclitaxel has superior efficacy in stage IV non-small cell lung cancer (NSCLC). Howbeit, there is limited research on the effects of combination therapy.

AIM

To determine the efficacy of anlotinib plus albumin-paclitaxel in stage IV NSCLC.

METHODS

Forty-two patients diagnosed with stage IV NSCLC who were treated at our hospital from January 2022 to February 2023 were selected as study subjects. According to the research protocol, the patients were divided into two groups: conventional therapy (albumin paclitaxel, n = 20) and combination therapy (anlotinib plus albumin paclitaxel, n = 22). The clinical effect, serum tumor markers, progression-free survival, overall survival, immune function, quality of life, mental state, and toxic side effects were compared between the two groups.

RESULTS

The disease remission rate, disease control rate, CD3+, CD4+, CD4+/CD8+ and Karnofsky Performance Scale (KPS) score in combined therapy were higher than conventional therapy. After treatment, levels of carcinoembryonic antigen, cytokeratin 19 fragment antigen 21-1, and vascular endothelial growth factor, self-rating anxiety scale, and self-rating depression scale score were all lower in combination therapy compared to conventional therapy. In addition, there was no remarkable difference in adverse reactions between the two groups.

CONCLUSION

Anlotinib combined with albumin-paclitaxel demonstrated therapeutic efficacy in stage IV NSCLC, reducing depression, anxiety, and tumor biomarker levels, while enhancing immune function, prolonging survival, and improving quality of life.

Keywords: Anlotinib; Albumin paclitaxel; Clinical effect; Immune function; Quality of life; Mental state

Core Tip: In this study, we evaluated the efficacy of anlotinib combined with albumin-paclitaxel in stage IV non-small cell lung cancer (NSCLC). Forty-two patients were split into two groups: one group received albumin-paclitaxel (n = 20), while the other group received anlotinib plus albumin-paclitaxel (n = 22). The study compared clinical outcomes, tumor markers, progression-free survival, overall survival, immune function, quality of life, mental health, and side effects. The combination therapy group showed higher disease remission and control rates, better immune markers and quality of life scores, and lower tumor biomarkers and mental health scores. Adverse reactions were similar in both groups. The combination of anlotinib plus albumin-paclitaxel was effective in treating stage IV NSCLC, reducing depression and anxiety, lowering tumor biomarkers, enhancing immune function, prolonging survival, and improving quality of life.